Jasper Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$83.9M | -$76.2M | -$68.9M | -$51.2M | -$36.8M |
| Operating expenses | $83.9M | $76.2M | $68.9M | $51.2M | $36.8M |
| Cost of revenue | $41.6M | $34.3M | — | — | — |
| Cash from operations | -$77.2M | -$62.6M | -$52.1M | -$45.9M | -$33.7M |
| Total assets | $35.8M | $79.9M | $94.9M | $48.4M | $93.7M |
| Total liabilities | $31.6M | $18.2M | $16.5M | $12.4M | $24.1M |
Shares outstanding 28.0M · Free float 26.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.